Fetal growth restriction (FGR) presents with an increased risk of stillbirth and childhood and adulthood morbidity. Melatonin, a neurohormone and antioxidant, has been suggested as having therapeutic benefit in FGR. We tested the hypothesis that melatonin would increase fetal growth in two mouse models of FGR which together represent a spectrum of the placental phenotypes in this complication: namely the endothelial nitric oxide synthase knockout mouse (eNOS) which presents with abnormal uteroplacental blood flow, and the placental specific knockout mouse (P0) which demonstrates aberrant placental morphology akin to human FGR.
View Article and Find Full Text PDF